FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US ...Middle East

STOCKHOLM, Jan. 14, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly...

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US )

Also on site :

• Born on One of These 4 Dates? You're a Wise, Old Soul
• Tony-Nominated Actress, 23, Makes Bold Declaration About Taylor Swift
• Blake Lively Wins Legal Battle Against Justin Baldoni